Clinical Trial Update: Evaluation of the Safety and Efficacy of HSK39004 Dry Powder Inhaler in Chinese Patients With Chronic Obstructive Pulmonary Disease (COPD) [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating the safety and efficacy of HSK39004 dry powder inhaler in Chinese patients with Chronic Obstructive Pulmonary Disease; the stu…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Obstructive Pulmonary Disease

Drugs mentioned

• HSK39004 Dry Powder Inhaler (HSK39004)

Snippet

Sponsor: Haisco Pharmaceutical Group Co., Ltd. | Conditions: Chronic Obstructive Pulmonary Disease (COPD) | Phase 2 | Status: ACTIVE_NOT_RECRUITING